Categories
Change Password!
Reset Password!
The study was
conducted to investigate the onset and sustainability of patient-reported
improvements in symptoms of PsA subjects after treatment with IXE up to Week
108.
PsA (Psoriatic
arthritis) causes painful joint inflammation. In patients
with PsA, the study assessing patient-reported improvements in signs and
symptoms with IXE (ixekizumab) treatment illustrated that IXE-treated patients
achieved substantially greater improvements and faster onset of improvements in
patient-reported outcomes in comparison with placebo. The responses were
generally consistent regardless of prior TNFi (tumor necrosis factor inhibitor)
experience and were sustained over 2 years.
The study was
conducted to investigate the onset and sustainability of patient-reported
improvements in symptoms of PsA subjects after treatment with IXE up to Week
108.
Patients with active PsA were randomized to either naive to
biological DMARDs (Disease-modifying anti-rheumatic drugs) (SPIRIT-P1) or
having inadequate response or intolerance to 1 or 2 prior TNF-i (TNFi-experienced;
SPIRIT-P2). A change from baseline in joint pain VAS (visual analogue scale;
0-100 scale), patient global assessment VAS (0-100 scale), fatigue NRS
(numerical rating scale, 0 to 10), and HAQ-DI (Health Assessment
Questionnaire-Disability Index, 0-3) was examined up to Week 108.
In patients treated with IXE, rapid and statistically significant improvement was witnessed in joint pain VAS, HAQ-DI, and patient global assessment as early as Week 1 when compared to the placebo group. This benefit was found to be sustained or increased through Week 108. In IXE-treated patients, the fatigue scores improved in comparison to placebo. At Week 24, the results were statistically significant only in SPIRIT-P2. Improvements in fatigue with IXE were sustained over 2 years. The improvements witnessed in these patient-reported outcomes were consistent in biologic-naive or TNFi-experienced individuals.
In
biologic-naive and TNF-inadequate responder patients with PsA, treatment with
IXE causes rapid and sustained improvements in patient-reported signs and
symptoms up to Week 108.
Clinical and Experimental Rheumatology
Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms With Ixekizumab in Biologic-Naive and TNF-inadequate Responder Patients With Psoriatic Arthritis
Ana-Maria Orbai et al.
Comments (0)